Compare Novo Nordisk A/S (NVO) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Nuscale Power Corporation — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Nuscale Power Corporation trades at $8.82 (market cap $2.76B). The key difference: Novo Nordisk A/S is far larger — about 79.9× Nuscale Power Corporation's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| NVO | SMR | |
|---|---|---|
Market Cap | $220.53B | $2.76B |
Sector | Health | Utilities |
52-Week High | $71.70 | $53.43 |
52-Week Low | $35.29 | $7.64 |
Enterprise Value | $239.49B | $1.87B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
SMR (NuScale Power) trades at $7.96, up 3.2% today but remains in a bearish technical trend. The company shows severe fundamental challenges with negative net income margins exceeding -2,000% and consecutive earnings misses. Despite these losses, analyst consensus remains optimistic with a $12.25 price target representing 54% upside potential, driven by nuclear energy's long-term prospects and the company's first-mover advantage in small modular reactors.
The stock presents a high-risk, high-reward opportunity. While current financials are deeply concerning with massive losses and negative cash flow, the potential nuclear energy renaissance and SMR's regulatory approvals offer substantial upside if commercialization succeeds. Investors face significant execution risk as the company burns cash while attempting to secure its first commercial reactor sale.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
